VectorY to Participate in the Jefferies and JP Morgan Healthcare Conferences
Amsterdam, The Netherlands, 26 October 2022 – VectorY Therapeutics, a biotech company focusing on the development of innovative vectorized antibody approaches for the treatment of neurodegenerative and muscular diseases, today announces participation in the Jefferies Healthcare Conference to be held November 15-17 in London, UK, and the JP Morgan Healthcare conference to be held January 9-12 in San Francisco, CA, USA.
VectorY management will be present at the conferences. In case you want to schedule a meeting please reach out to Sariette Witte, Head of Communications via sariette.witte@vectorytx.com.
About VectorY
VectorY combines the therapeutic potential of antibodies and gene therapy to develop long-lasting therapeutic solutions for neurodegenerative and muscular diseases with high unmet medical need such as Amyotrophic Lateral Sclerosis (ALS) and Huntington’s disease.
VectorY is a fully integrated gene therapy company focused on the development of innovative therapeutics based on a novel AAV gene therapy platform, antibody-based targeted protein degradation technologies and proprietary manufacturing technology. While focusing initially on neurodegenerative and muscular diseases, VectorY's synergistic technologies may be applied across a wide range of indications.
VectorY was founded in October 2020 and is based on the Amsterdam Science Park.
For more information, see www.vectorytx.com.
Contacts
VectorY B.V.
Sariette Witte, Head of Communications
E-mail: sariette.witte@vectorytx.com
Tel: +31 681 174 072
Instinctif Partners (media enquiries)
Melanie Toyne-Sewell / Giulia Lasagni / Manisha Kuttetira
E-mail: VectorY@instinctif.com
Tel: +44 20 7457 2020
